An observational study in Aortic Valve Stenosis and Myocardial Fibrosis, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Norwegian University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Aortic Valve Stenosis with a site in Norway — 2 open to participants now, 4 under way, none of them phase 3. Aortic Valve Stenosis · Norway.
Among the 22 studies in Aortic Valve Stenosis with a site in Norway, this one is the 11th largest by enrollment of the 15 observational ones that give a count, is one of 3 that started in 2025, is one of 15 observational ones, and was the 18th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →2 of the 22 studies in Aortic Valve Stenosis with a site in Norway are open now. Recruiting first, the newest first:
Ole De Backer · Sites in Norway, Belgium, Denmark and 3 more countries
Ages 18+
Abbott Medical Devices · Sites in Norway, Australia, France and 5 more countries
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 7 interventional studies, 500 across the 15 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.
Norwegian University of Science and Technology has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Aortic Valve Stenosis with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a long term follow-up of patients that were included as part of a previous study (NCT03422770), where patients with aortic stenosis and healthy controls went through echocardiography, cardiac MRI, long-term ECG-recording, blood tests and quality of life assessment. Echocardiography included high frame ultrasound for detection of natural mechanical waves, and the measured speed of these waves were used as a marker of the extent of myocardial fibrosis.
Up to five years have now passed since inclusion at baseline, and a proportion of the patients in the cohort have undergone aortic valve replacement at some point. In this study, the investigators will repeat the cardiac imaging (echocardiography and cardiac MRI), ECG and blood test, to assess long-term changes in myocardial fibrosis in aortic stenosis patients.
High frame rate ultrasound with quantification of myocardial mechanical wave velocities provides a new approach to evaluation of myocardial stiffness.
Principle: An elastic medium (the left ventricle) is incited by a force (naturally occuring mechanical wave generated by atrial contraction and/or closure of mitral and aortic valve), and the resulting oscillation wave propagates through the medium with a speed that depends only on the density and stiffness of the medium. If the density of the medium is known, measuring the propagation velocity of the wave is the same as measuring the stiffness of the medium.
There is a lack of longitudinal data in this research area. A follow-up study of the described cohort, will add valuable insight into high frame rate ultrasound as a potential tool to quantify myocardial fibrosis in heart failure patient, and to monitor any changes from baseline.
Patients: Mild, moderate, or severe aortic valve stenosis. A subset of the patients will have undergone aortic valve replacement since inclusion.
Controls: Healthy with no valve disease, or other cardiac disease known to cause myocardial fibrosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mild aortic stenosis:25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. Moderate aortic stenosis: 25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. Severe aortic stenosis: 50 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
Diagnostic Test: High frame rate echocardiography · Diagnostic Test: MRI · Diagnostic Test: Blood test · Diagnostic Test: ECG and Holter-ECG · Diagnostic Test: 6 min walking test
The controls from baseline inclusion will be invited to undergo repeat echocardiography, blood test and CMRI
Diagnostic Test: High frame rate echocardiography · Diagnostic Test: MRI · Diagnostic Test: Blood test
Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
Also known as: GE Vingmed ultrasound scanner E95, 2017
Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
Also known as: Cardiac magnetic resonance imaging (CMRI)
Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
Cardiovascular morbidity
Admissions with heart failure
Time frame: 5 year
Cardiovascular mortality
Death caused by cardiac disease
Time frame: 5 year
All cause mortality
Mortality in general
Time frame: 5 years
Time of first re-hospitalization
Time of first re-hospitalization after inclusion
Time frame: 5 years
Cardiac systolic function
Systolic function based on left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Unit of measure for LVEF and for GLS is % for both (a positive number for LVEF, and a negative number for GLS)
Time frame: 5 years
Cardiac diastolic function (1 of 5)
Echocardiographic diastolic function based on i) left atrial volume index {ml/m\^2).
Time frame: 5 years
Cardiac diastolic function (2 of 5)
Echocardiographic diastolic function based on ii) mitral annular velocities {cm/sec}
Time frame: 5 years
Cardiac diastolic function (3 of 5)
Echocardiographic diastolic function based on iii) mitral inflow velocities {cm/sec}
Time frame: 5 years
Cardiac diastolic function (4 of 5)
Echocardiographic diastolic function based on iv) ricuspid regurgitation velocity {cm/sec}
Time frame: 5 years
Cardiac diastolic function (5 of 5)
Echocardiographic diastolic function based on v) E/è-ratio
Time frame: 5 years
Velocity of natural mechanical waves propagating through the myocardium
Investigate for prognotisc value and if it can be a marker of diastolic dysfunction. Unit of velocity measurement is m/sec.
Time frame: 5 years
Plan to share: Undecided
Ran from Jan 2025 to primary completion in Jun 2026, 16 months.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's 16 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Mar 2026 → Jun 2026 and completion Apr 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →